News

Data generated from this agreement will demonstrate the combination of the unique Advaxis immunotherapy platform, which generates both tumor fighting T cells and reduces tumor protection inside the

The company is developing EPI-743 for pediatric and adult mitochondrial disease, including Friedreich’s ataxia. In the recently completed Phase I and multiple Phase II trials, EPI-743 has been

Findings from a pre-specified retrospective analysis of patients showed that talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts

The antifungal agent is also marketed as NOXAFIL (100mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension. The company said that NOXAFIL injection, delayed-release tablets and oral suspension

The patent includes claims to protect the use of a clinical-stage drug candidate BL-8040’s composition for improving immune responses to an antigen, such as a tumor-associated antigen. The

The pivotal Phase III POISE trial showed that OCA, at both a 10mg dose and a 5mg dose titrated to 10mg, met the trial’s primary endpoint of achieving

The particulate matter was found in a small number of vials in the three packaged lots of VPRIV. A Shire investigation identified the particulate matter root cause as

Pfizer Global Innovative Pharmaceuticals Business Medicines Development Group head and senior vice president Dr Steven J Romano noted as the number of hip and knee replacement surgeries performed

SmartFactory is a single-use cGMP bio-manufacturing capacity, which will allow Alvotech to rapidly expand its biosimilars business. Finesse’s customers will benefit from unprecedented access to Alvogen’s commercial, the